Polyrizon Ltd. (PLRZ) Stock: Company Closes $4 Million Deal With Institutional Investor

TLDR

• Polyrizon closes a $4 million financing with a single institutional buyer
• PLRZ falls 3.34% to $12.00 after the company completes the September financing
• Registered direct offering includes 232,500 ordinary shares and 30,000 warrants
• Private placement adds 70,833 pre-funded warrants and 333,333 common warrants
• Polyrizon plans to use the net proceeds for working capital and corporate needs

Polyrizon Ltd. (PLRZ) shares traded at $12.00, down 3.34%, after the company completed a $4 million financing. The biotech company closed a registered direct offering and concurrent private placement with one institutional buyer on September 4. The transaction adds working capital, while newly issued shares and potential warrant exercises expand the company’s outstanding equity base.

Polyrizon Ltd., PLRZ

Polyrizon Completes $4 Million Financing

Polyrizon sold 333,333 units and pre-funded units at a combined price of $12.00 for each unit in the financing. Each unit included one ordinary share, or one pre-funded warrant, together with one common warrant for another ordinary share. The company structured the transaction through a registered direct sale and a simultaneous private placement with the same buyer.

Under the registered direct portion, Polyrizon issued 232,500 ordinary shares and 30,000 pre-funded warrants to the institutional buyer. The company priced each ordinary share at $12.00 and each pre-funded warrant at $11.99999 under the transaction terms. Those pre-funded warrants carry a nominal $0.00001 exercise price and remain immediately exercisable until holders exercise them completely.

The private placement added 70,833 PIPE pre-funded warrants and 333,333 PIPE common warrants to the overall financing package. The common warrants carry a $12.00 exercise price, matching the combined unit price used across the September financing transaction. Meanwhile, the PIPE pre-funded warrants require registration before exercise because the company issued them through the unregistered placement.

New Shares and Warrants Expand Dilution Exposure

The financing increased Polyrizon’s share count because the company issued 232,500 ordinary shares through the registered offering. Additional shares can enter circulation when holders exercise pre-funded warrants, subject to the applicable registration terms for PIPE securities. Common warrant exercises could create further dilution because each warrant allows its holder to purchase one additional ordinary share.

Pre-funded warrants function differently from standard warrants because buyers pay nearly the full share purchase price when acquiring the instrument. Therefore, holders only need to pay the nominal exercise amount before receiving the related ordinary shares after satisfying applicable conditions. This structure can make conversion more likely because the remaining exercise cost stands far below the ordinary share purchase price.

Existing shareholders may consequently own a smaller percentage of Polyrizon after the company issues shares tied to these financing instruments. However, the transaction also provides fresh capital that Polyrizon can deploy across operations and other general corporate requirements. The balance between added liquidity and expanded share supply now forms the main financial context surrounding the completed transaction.

Polyrizon Plans Capital for Working Needs

Polyrizon expects to combine the financing proceeds with existing cash for general corporate purposes and working capital requirements. The company reported approximately $4 million in gross proceeds before placement fees, legal expenses, and other transaction-related costs. Consequently, the amount available for operations will remain below the stated gross proceeds after Polyrizon pays those financing expenses.

Aegis Capital acted as the exclusive placement agent, while legal advisers supported Polyrizon and the placement agent during closing. The registered direct offering relied on Polyrizon’s effective Form F-3 shelf registration statement declared effective in December 2025. The company also agreed to file registration statements covering resale of shares linked to securities issued through the private placement.

Polyrizon remains a development-stage biotechnology company focused on intranasal hydrogel products delivered through nasal spray applications and related platforms. Its Capture and Contain technology aims to form a thin nasal barrier that limits contact with viruses and allergens. The company also develops Trap and Target technology for intranasal delivery of active pharmaceutical ingredients during earlier preclinical development stages.

The post Polyrizon Ltd. (PLRZ) Stock: Company Closes $4 Million Deal With Institutional Investor appeared first on Blockonomi.